

Chemicals/Finland, May 3, 2021 Company update

Multiples are rerating

Exel's record Q1 orders surprised. In our view the next quarters' orders determine how much forward-look the multiples warrant. Our TP is EUR 11, now rate HOLD (BUY).

The EUR 42m order intake sets a new benchmark level


Exel's Q1 revenue grew 11% y/y to EUR 31m and was a bit above our EUR 30m estimate. Customer industries performed close to our expectations while Asia-Pacific contributed most of the growth. Adj. EBIT was EUR 2.5m vs our EUR 2.4m estimate. Strong demand was to be expected, yet the EUR 42m order intake (up 22% y/y from a high comparison figure) is a record and can be compared to the EUR 30m level Exel has averaged in the recent past. The orders stemmed from many industries and no large orders drove the intake. Operations ran almost as usual despite the pandemic, raw materials, and logistics issues. Exel managed to balance its raw material pool across the eight plants.

Organic CAGR outlook now closer to 10% than 5%

Exel already saw some raw materials inflation affecting Q1 margins. We expect a more pronounced negative effect in Q2 (we now estimate 7.2% Q2 EBIT vs our prev. 10.4% estimate), but also see EBIT margins bounce back to ca. 9-10% levels in H2. Exel has been able to pass raw materials inflation forward before and this is to be expected again considering the value chain position. Profitability slope remains attractive especially if the Q1 order levels continue to persist over the summer. We don't consider the EUR 42m figure just a fluke and even if Exel may not quite reach such high orders in the coming quarters we nevertheless see the company is now positioned for high single-digit organic CAGR for years to come. In our view Exel might well reach double-digit top line growth this year and we see such growth rates driving long-term EBIT margins meaningfully above 10%.

Earnings multiples have already rerated for a valid reason

Exel is valued ca. 9.5x EV/EBITDA and 15x EV/EBIT on our FY '21 estimates. The multiples are a bit high compared to the historical respective averages of 8x and 13x but in our view warranted by the current growth prospects. Top line growth continues to drive profitability and the multiples are some 8.5x and 12x on our FY '22 estimates. In our opinion the next few quarters' orders will determine how much forward into the future the multiples may lean. We retain our EUR 11 TP, rating now HOLD (BUY).



10.88
11.0
03-May-21
16-Apr-21
YES
11,897
11,897
129
100.0
1.20
EXL1V.HE
EXL1V FH
0.1
20-Jul-21
www.exelcomposites.com
Joonas Ilvonen
joonas.ilvonen@evli.com
+358 44 430 9071

■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield	DPS EUR
2019	103.8	5.1	4.9%	0.7	0.20	32.5	1.0	21.0	0.9	0.18
2020	108.6	9.4	8.7%	0.5	0.45	16.4	1.1	12.5	0.5	0.20
2021E	119.6	10.3	8.6%	5.5	0.61	17.7	1.3	15.2	4.2	0.25
2022E	128.5	12.7	9.9%	7.6	0.77	14.1	1.2	11.9	5.9	0.30
2023E	136.2	13.6	10.0%	8.5	0.84	13.0	1.1	10.8	6.5	0.32
Market cap	o, EURm		129 G	earing 2021E,	0/0		80.3 CAGR	EPS 2020-2	3, %	23.0
Net debt 2	021E, EURm		27 Pi	rice/book 2021	ΙE		3.8 CAGR	sales 2020-	23, %	7.8
Enterprise	value, EURm		156 D	ividend yield 2	.021E, %		2.3 ROE 2	021E, %		23.5
Total asset	s 2021E, EURn	n	102 Ta	ax rate 2021E,	0/0			14.5		
Goodwill 2	021E, EURm		13 Ec	quity ratio 202	21E, %			1.2		



Chemicals/Finland, May 3, 2021 Company update

Estimates and peer group multiples

Exel Composites	2019	Q1'20	Q2'20	Q3'20	Q4'20	2020	Q1'21	Q2'21e	Q3'21e	Q4'21e	2021e
Buildings and infrastructure	23.5	6.2	5.3	4.9	7.0	23.5	7.0	5.9	5.4	7.5	25.8
Equipment and other industries	18.6	6.1	4.0	4.3	5.1	19.5	5.6	4.3	4.6	5.5	20.1
Wind power	23.6	5.8	7.9	7.8	6.6	28.1	7.4	8.9	8.7	7.2	32.3
Machinery and electrical	14.4	3.8	4.8	3.3	3.7	15.5	3.7	5.1	3.4	3.9	16.1
Transportation	13.1	3.4	2.8	2.2	1.9	10.2	2.5	2.1	2.3	1.9	8.8
Defense	2.3	1.3	0.8	1.9	1.4	5.3	2.2	1.5	2.2	1.6	7.6
Telecommunications	8.2	1.2	1.7	1.7	1.8	6.5	2.5	2.6	1.9	2.0	8.9
Revenue	103.8	27.8	27.2	26.0	27.5	108.6	31.0	30.4	28.5	29.7	119.6
y/y change, %	7 %	3 %	3 %	10 %	3 %	5 %	11 %	12 %	10 %	8 %	10 %
Adjusted EBIT	7.2	2.1	2.9	2.0	2.7	9.7	2.5	2.2	2.6	3.1	10.4
EBIT	5.1	1.9	2.8	2.0	2.7	9.4	2.4				10.3
-margin, %	6.9 %	7.5 %	10.6 %	7.8 %	9.9 %	8.9 %	7.9 %	7.2 %	9.1 %	10.4 %	8.7 %
-margin (reported), %	4.9 %	6.7 %	10.2 %	7.8 %	9.9 %	8.7 %	7.8 %				8.6 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	20	21	22	20	21	22	20	21	22
Gurit Holding	1012	15.7x	15.3x	14.3x	18.9x	18.9x	17.5x	11.1 %	10.5 %	11.1 %
Hexagon Composites	1113	58.0x	94.2x	33.7x			239.5x	-1.9 %	-3.8 %	0.9 %
Hexcel	3926	26.6x	28.0x	17.1x	351.9x	99.5x	29.9x	0.9 %	4.0 %	11.3 %
Avient	3850	13.0x	11.3x	10.5x	18.9x	15.6x	14.3x	8.1 %	9.3 %	9.6 %
SGL Carbon	757	7.1x	10.1x	7.8x		32.5x	17.2x	-11.1 %	3.4 %	6.1 %
TPI Composites	1621	22.7x	17.4x	13.1x	85.8x	33.6x	20.8x	1.5 %	3.6 %	5.2 %
Peer Group Average	2046	23.9x	29.4x	16.1x	118.9x	40.0x	56.5x	1.4 %	4.5 %	7.4 %
Peer Group Median	1367	19.2x	16.4x	13.7x	52.4x	32.5x	19.1x	1.2 %	3.8 %	7.9 %
Exel Composites (Evli est.)	129	7.7x	9.6x	8.3x	12.5x	15.2x	11.9x	8.7 %	8.6 %	9.9 %
Exel Composites prem./disc. to peer media	an	-60 %	-41 %	-39 %	-76 %	-53 %	-38 %	612 %	127 %	26 %

Source FactSet, Evli Research

Chemicals/Finland, May 3, 2021 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	10.88 PV of Free Cash Flow	74 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	11.21 PV of Horizon value	91 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	3.0 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	12.3 Marketable securities	12 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	10.2 Debt - dividend	-44 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	55.2 Value of stock	133 Nr of shares, Mn	11.9 Effective tax rate, %	21

												1
DCF valuation, EURm	2020	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	Horizon
Net sales	109	120	129	136	143	147	151	154	157	160	163	165
Sales growth, %	4.6	10.1	7.5	6.0	5.0	3.0	2.5	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	9	10	13	14	15	15	16	16	17	18	19	19
Operating income margin, %	8.7	8.6	9.9	10.0	10.5	10.5	10.5	10.5	11.0	11.5	11.5	11.5
+ Depreciation+amort.	6	6	6	6	6	6	6	5	5	5	5	
EBITDA	15	16	18	19	21	21	22	21	23	24	24	
- Paid taxes	-3	-2	-3	-3	-4	-4	-4	-4	-4	-4	-4	
- Change in NWC	3	-1	-1	-1	-1	-1	0	0	0	0	0	
NWC / Sales, %	11.2	11.3	11.3	11.4	11.4	11.4	11.5	11.5	11.5	11.5	11.5	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-13	-5	-5	-5	- 5	-5						
opCAPEX / Sales, %	11.9	5.5	4.7	4.5	4.4	4.2	4.2	3.7	3.7	3.7	3.6	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	2	8	9	10	11	12	12	12	13	14	14	202
= Discounted FCFF		7	8	8	8	8	8	7	7	7	6	91
		•			•	•		•				
= DFCF min WACC		7	8	8	8	8	8	7	7	7	7	103
= DFCF max WACC		7	8	8	8	8	8	7	7	6	6	82

Chemicals/Finland, May 3, 2021 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2020Q1	2020Q2	2020Q3	2020Q4	2020	2021Q1	2021Q2E	2021Q3E	2021Q4E	2021E	2022E	2023E
Net sales	27.8	27.2	26.1	27.5	108.6	31.0	30.4	28.5	29.7	119.6	128.5	136.2
EBITDA	3.4	4.3	3.5	4.1	15.3	3.9	3.7	4.1	4.6	16.3	18.3	19.2
EBITDA margin (%)	12.1	15.8	13.5	14.8	14.0	12.7	12.2	14.4	15.5	13.7	14.2	14.1
EBIT	1.9	2.8	2.0	2.7	9.4	2.4	2.2	2.6	3.1	10.3	12.7	13.6
EBIT margin (%)	6.7	10.3	7.8	9.9	8.7	7.8	7.2	9.1	10.4	8.6	9.9	10.0
Net financial items	-0.6	0.2	-0.7	-1.2	-2.3	0.5	-0.4	-0.4	-0.4	-0.7	-0.6	-0.5
Pre-tax profit	1.3	2.9	1.3	1.5	7.1	2.9	1.8	2.2	2.7	9.6	12.1	13.1
Tax	-0.6	-0.4	-0.2	-0.4	-1.7	-0.9	-0.4	-0.5	-0.6	-2.3	-2.9	-3.1
Tax rate (%)	49.4	15.3	15.1	29.7	24.6	30.8	21.0	21.0	21.0	24.0	24.0	24.0
Net profit	0.7	2.5	1.1	1.1	5.4	2.0	1.4	1.7	2.1	7.3	9.2	10.0
EPS	0.06	0.21	0.09	0.09	0.45	0.17	0.12	0.15	0.18	0.61	0.77	0.84
EPS adjusted (diluted no. of shares)	0.06	0.21	0.09	0.09	0.45	0.17	0.12	0.15	0.18	0.61	0.77	0.84
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.25	0.30	0.32
SALES, EURm												
Exel Composites	27.8	27.2	26.1	27.5	108.6	31.0	30.4	28.5	29.7	119.6	128.5	136.2
Total	27.8	27.2	26.1	27.5	108.6	31.0	30.4	28.5	29.7	119.6	128.5	136.2
SALES GROWTH, Y/Y %												
Exel Composites	2.6	2.6	10.5	3.4	4.6	11.3	11.8	9.2	7.9	10.1	7.5	6.0
Total	2.6	2.6	10.5	3.4	4.6	11.3	11.8	9.2	7.9	10.1	7.5	6.0
EBIT, EURm												
Exel Composites	1.9	2.8	2.0	2.7	9.4	2.4	2.2	2.6	3.1	10.3	12.7	13.6
Total	1.9	2.8	2.0	2.7	9.4	2.4	2.2	2.6	3.1	10.3	12.7	13.6
EBIT margin, %							_	_	_			
Exel Composites	6.7	10.3	7.8	9.9	8.7	7.8	7.2	9.1	10.4	8.6	9.9	10.0
Total	6.7	10.3	7.8	9.9	8.7	7.8	7.2	9.1	10.4	8.6	9.9	10.0

Chemicals/Finland, May 3, 2021 Company update

INCOME STATEMENT, EURm	2016	2017	2018	2019	2020	2021E	2022E	2023E
Sales	73.1	86.3	96.6	103.8	108.6	119.6	128.5	136.2
Sales growth (%)	-8.9	18.1	11.9	7.5	4.6	10.1	7.5	6.0
EBITDA	3.8	9.3	7.7	10.7	15.3	16.3	18.3	19.2
EBITDA margin (%)	5.2	10.8	8.0	10.3	14.0	13.7	14.2	14.1
Depreciation	-3.2	-3.2	-5.5	-5.6	-5.8	-6.0	-5.6	-5.6
EBITA	0.6	6.1	2.2	5.1	9.4	10.3	12.7	13.6
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	0.6	6.1	2.2	5.1	9.4	10.3	12.7	13.6
EBIT margin (%)	0.8	7.1	2.3	4.9	8.7	8.6	9.9	10.0
Reported EBIT	-1.2	6.1	2.2	5.1	9.4	10.3	12.7	13.6
EBIT margin (reported) (%)	-1.6	7.1	2.3	4.9	8.7	8.6	9.9	10.0
Net financials	-0.1	-0.7	-0.5	-1.2	-2.3	-0.7	-0.6	-0.5
Pre-tax profit	0.5	5.4	1.7	3.9	7.1	9.6	12.1	13.1
Taxes	-0.2	-1.2	-1.3	-1.5	-1.7	-2.3	-2.9	-3.1
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	-1.4	4.2	0.4	2.4	5.4	7.3	9.2	10.0
Cash NRIs	-1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	17	16	21	23	30	30	31	31
Goodwill	10	13	13	13	13	13	13	13
Right of use assets	0	0	5	5	3	4	4	4
Inventory	9	12	15	17	16	18	19	20
Receivables	10	15	20	20	21	23	25	26
Liquid funds	7	8	5	7	12	13	14	15
Total assets	54	64	79	85	97	102	107	111
Liabilities								
Shareholder's equity	27	29	26	26	29	34	40	46
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	0	3	4	2	4	4	4
Deferred taxes	1	0	0	0	0	0	0	0
Interest bearing debt	14	16	30	32	40	37	33	28
Non-interest bearing current liabilities	12	18	18	21	24	26	28	30
Other interest-free debt	1	0	2	2	2	2	2	2
Total liabilities	54	64	79	85	97	102	107	111
CASH FLOW, EURm								
+ EBITDA	4	9	8	11	15	16	18	19
- Net financial items	0	-1	0	-1	-2	-1	-1	-1
- Taxes	0	-1	-2	-2	-2	-2	-3	-3
- Increase in Net Working Capital	1	-3	-4	1	3	-1	-1	-1
+/- Other	-1	1	0	0	0	0	0	0
= Cash flow from operations	3	5	1	8	13	12	14	15
- Capex	-3	-3	-10	-8	-13	-7	-6	-6
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	0	1	-9	1	0	5	8	8
+/- New issues/buybacks	0	-1	0	0	-1	0	0	0
- Paid dividend	-3	-1	-4	-2	-2	-2	-3	-4
+/- Other	2	1	9	3	7	-2	-4	-4

Chemicals/Finland, May 3, 2021 Company update

KEY FIGURES	2017	2018	2019	2020	2021E	2022E	2023E
M-cap	78	48	78	88	129	129	129
Net debt (excl. convertibles)	9	28	29	30	27	22	18
Enterprise value	87	76	107	118	156	152	147
Sales	86	97	104	109	120	129	136
EBITDA	9	8	11	15	16	18	19
EBIT	6	2	5	9	10	13	14
Pre-tax	5	2	4	7	10	12	13
Earnings	4	0	2	5	7	9	10
Equity book value (excl. minorities)	29	26	26	29	34	40	46
Valuation multiples							
EV/sales	1.0	0.8	1.0	1.1	1.3	1.2	1.1
EV/EBITDA	9.3	9.9	10.0	7.7	9.6	8.3	7.6
EV/EBITA	14.2	34.5	21.0	12.5	15.2	11.9	10.8
EV/EBIT	14.2	34.5	21.0	12.5	15.2	11.9	10.8
EV/OCF	17.7	84.3	12.9	8.8	13.1	11.1	10.1
EV/FCFF	-28.4	-6.6	32.5	53.3	20.5	16.5	14.6
P/FCFE	55.8	-5.5	110.9	185.6	23.7	17.1	15.3
P/E		119.0	32.5		17.7		13.0
r/c P/B	18.6			16.4	3.8	14.1	
•	2.7	1.8	3.0	3.1		3.2	2.8
Target EV/EBITDA	0.0	0.0	0.0	0.0	9.7	8.4	7.7
Target EV/EBIT	0.0	0.0	0.0	0.0	15.3	12.0	10.9
Target EV/FCF	0.0	0.0	0.0	0.0	28.9	20.2	17.5
Target P/B	0.0	0.0	0.0	0.0	3.9	3.3	2.8
Target P/E	0.0	0.0	0.0	0.0	17.9	14.2	13.1
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.35	0.03	0.20	0.45	0.61	0.77	0.84
Operating cash flow per share	0.41	0.08	0.70	1.12	1.01	1.15	1.23
Free cash flow per share	0.12	-0.73	0.06	0.04	0.46	0.64	0.71
Book value per share	2.42	2.16	2.21	2.41	2.83	3.35	3.89
Dividend per share	0.30	0.18	0.18	0.20	0.25	0.30	0.32
Dividend payout ratio, %	85.0	535.4	89.2	44.5	40.7	38.8	38.3
Dividend yield, %	4.6	4.5	2.7	2.7	2.3	2.8	2.9
FCF yield, %	1.8	-18.3	0.9	0.5	4.2	5.9	6.5
Efficiency measures							
ROE							
	15.2	1.5	9.2	19.4	23.5	25.0	23.1
ROCE	15.2 14.6	1.5 4.5	9.2 8.6	19.4 14.3	23.5 14.5	25.0 17.2	23.1 17.8
ROCE Financial ratios							
Financial ratios	14.6	4.5	8.6	14.3	14.5	17.2	17.8
Financial ratios Inventories as % of sales	14.6	4.5 15.7	16.3	14.3	14.5	17.2	17.8
Financial ratios Inventories as % of sales Receivables as % of sales	14.6 13.5 17.1	15.7 20.8	16.3 19.2	14.3 14.9 19.2	14.5 14.9 19.2	17.2 14.9 19.2	17.8 14.9 19.2
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	14.6 13.5 17.1 21.4	4.5 15.7 20.8 19.2	16.3 19.2 20.2	14.3 14.9 19.2 22.0	14.5 14.9 19.2 22.0	17.2 14.9 19.2 22.0	17.8 14.9 19.2 22.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	13.5 17.1 21.4 9.3	4.5 15.7 20.8 19.2 16.1	8.6 16.3 19.2 20.2 14.1	14.9 19.2 22.0 11.2	14.5 14.9 19.2 22.0 11.3	17.2 14.9 19.2 22.0 11.3	17.8 14.9 19.2 22.0 11.4
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	13.5 17.1 21.4 9.3 4.1 4.1	15.7 20.8 19.2 16.1 9.9 9.9	16.3 19.2 20.2 14.1 7.3 7.3	14.3 14.9 19.2 22.0 11.2 11.9	14.5 14.9 19.2 22.0 11.3 5.5 5.5	17.2 14.9 19.2 22.0 11.3 4.7 4.7	17.8 14.9 19.2 22.0 11.4 4.5 4.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	13.5 17.1 21.4 9.3 4.1	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5	16.3 19.2 20.2 14.1 7.3	14.3 14.9 19.2 22.0 11.2 11.9	14.5 14.9 19.2 22.0 11.3 5.5	17.2 14.9 19.2 22.0 11.3 4.7 4.7 0.5	17.8 14.9 19.2 22.0 11.4 4.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	13.5 17.1 21.4 9.3 4.1 4.1 -0.3 0.9	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5 3.7	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	14.3 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	14.5 14.9 19.2 22.0 11.3 5.5 5.5 0.5 1.7	17.2 14.9 19.2 22.0 11.3 4.7 4.7 0.5 1.2	17.8 14.9 19.2 22.0 11.4 4.5 4.5 0.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	13.5 17.1 21.4 9.3 4.1 4.1 -0.3	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.3 14.9 19.2 22.0 11.2 11.9 11.9 0.1	14.5 14.9 19.2 22.0 11.3 5.5 5.5 0.5	17.2 14.9 19.2 22.0 11.3 4.7 4.7 0.5	17.8 14.9 19.2 22.0 11.4 4.5 4.5

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 3, 2021 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Skandinaviska Enskilda Banken AB	1,427,256	15.529	12.0%
Nordea Bank ABP	1,065,975	11.598	9.0%
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	8.704	6.7%
OP-Finland Small Firms Fund	598,259	6.509	5.0%
Danske Invest Finnish Equity Fund	546,650	5.948	4.6%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	443,541	4.826	3.7%
Phoebus Fund	311,348	3.387	2.6%
Säästöpankki Pienyhtiöt	288,710	3.141	2.4%
Nelimarkka Heikki Antero	242,836	2.642	2.0%
Ilmarinen Mutual Pension Insurance	242,733	2.641	2.0%
Ten largest	5,967,308	64.924	50%
Residual	5,929,535	64.513	50%
Total	11,896,843	129.438	100%

EARNINGS CALENDAR	
July 20, 2021	Q2 report
November 04, 2021	Q3 report
OTHER EVENTS	

COMPAI	NY MISCE	LLANFOUS

CEO: Riku Kytömäki CFO: Mikko Kettunen IR: Noora Koikkalainen

Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, May 3, 2021 Company update

DEFINITIONS

P/E	EPS	
176	LI J	
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares	
P/BV	DPS	
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share	
Market cap	OCF (Operating cash flow)	
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments	
EV (Enterprise value)	FCF (Free cash flow)	
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments	
EV/Sales	FCF yield, %	
Enterprise value Sales	Free cash flow Market cap	
ev/ebitda	Operative CAPEX/sales	
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales	
EV/EBIT	Net working capital	
Enterprise value Operating profit	Current assets – current liabilities	
Net debt	Capital employed/Share	
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares	
Total assets	Gearing	
Balance sheet total	<u>Net debt</u> Equity	
Div yield, %	Debt/Equity, %	
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions	
Payout ratio, %	Equity ratio, %	
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans	
ROCE, %	CAGR, %	
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year	
ROE, %		
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)		

Chemicals/Finland, May 3, 2021 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [3.5.2021, 9:25]. This report has been published on [3.5.2021, 9:40].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or EVIi. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 3, 2021 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, May 3, 2021 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sa	iles	Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto Evli Investment Solutions	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919 +358 40 352 6175
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001